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Abstract
Background:  Several studies showed that gain-of-function somatic mutations affecting the
catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to
gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung
carcinomas were shown to have ERBB2 mutations in the kinase domain. In our study, we sought to
determine if similar respective gain-of-function EGFR  and  ERBB2  mutations were present in
hepatoma and/or biliary cancers.
Methods: We extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples,
and 44 adenocarcinomas of the lung, this latter as a positive control for mutation detection. We
subjected those samples to PCR-based semi-automated double stranded nucleotide sequencing
targeting exons 18–21 of EGFR and ERBB2. All samples were tested against matched normal DNA.
Results: We found 11% of hepatoma, but no biliary cancers, harbored a novel ERBB2 H878Y
mutation in the activating domain.
Conclusion: These newly described mutations may play a role in predicting response to EGFR-
targeted therapy in hepatoma and their role should be explored in prospective studies.
Background
Mutations in the protein-kinase enzyme family, such as
the epidermal growth factor receptor (EGFR,  ERBB2),
found in human cancers are being investigated as promis-
ing targets for the development of novel antitumor thera-
pies.EGFR is the first described member of a family of
related transmembrane receptor tyrosine kinases. It is
comprised of the following four related receptors: EGFR
itself (ERBB1  or HER1), ERBB2  (HER2/neu),  ERBB3
(HER3) and ERBB4  (HER4).  ERBB  receptors are com-
posed of an extracellular ligand-binding domain, a trans-
membrane segment, and an intracellular protein tyrosine
kinase domain. These receptors trigger downstream sign-
aling pathways that are complex and multilayered. Dereg-
ulation of those ERBB receptors can lead to malignant
transformation. These receptors form either homo- or het-
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erodimeric complexes which provides amplification and
diversification [1]. Heterodimerization of the ERBB2 and
EGFR  is associated with a more robust signaling than
homodimerization [2]. Several studies showed that gain-
of-function somatic mutations affecting the catalytic
domain (specifically the ATP binding site, exons 18–21)
of EGFR in non-small cell lung carcinomas were strongly
associated with response to gefitinib and erlotinib, both
related EGFR-tyrosine kinase inhibitors (TKI) [3-5]. More
recently, a number of studies reported the presence of
ERBB2 mutations located in the kinase domain (exons 19
and 20) in non-small cell lung carcinomas (NSCLC) that
could potentially result in the activation of the tyrosine
kinase activity of the receptor protein [6-9]. In addition to
NSCLC, mutations in the ERBB2  kinase domain were
described in gastric, colorectal, and breast cancers [10,11].
In our study, we sought to determine if similar respective
gain-of-function  EGFR  and  ERBB2  mutations were
present in hepatoma and biliary cancers to determine the
potential for ERBB -targeted therapy.
Hepatoma is the most common malignant tumor of the
liver with a clear rising incidence in the number of cases
in the United States, and is largely attributed to the
increase in hepatitis C related liver disease [12]. Cancers of
the biliary tract are the second most common primary
hepatobiliary cancer [13]. There is no satisfactory treat-
ment available for patients with hepatobiliary cancers and
chemotherapy has been extremely disappointing.
The poor prognosis of patients with hepatoma and biliary
cancers in addition to the lack of satisfactory therapy for
advanced cases indicates a need for more effective thera-
peutic options. EGFR  signaling is implicated in both
hepatic and biliary carcinogenesis. Studies indicate that
EGFR is expressed in up to 85% and 80% of hepatoma
and biliary cancers, respectively [14], and EGF might be
required for the growth of those cells [15,16]. ERBB2 is
also expressed in a significant number of hepatoma and
biliary cancers acting as an independent prognostic factor
and a major contributor to carcinogenesis [17-21].
Recently, a multi-center phase 2 study looked at the effi-
cacy and tolerability of erlotinib in advanced hepatoma
and biliary cancers with encouraging results [22,23]. In
hepatoma, the reported PFS at 6 months of 32% with dis-
ease control (PR + SD) of 59% for a median duration of 4
months. The median overall survival (OS) was 13
months. In biliary cancers, the reported PFS at 6 months
was 25% with disease control (PR + SD) of 55% for a
median duration of 5.4 months. The median OS was 9
months.
Methods
In our study, we extracted genomic DNA from 40
hepatoma (18) and biliary cancers (22) samples, and 44
adenocarcinoma of the lung, the latter as a positive con-
trol for mutation detection. All hepatobiliary samples
were paraffin-embedded while all lung samples were fro-
zen. Hepatoma and biliary cancers were subjected to laser
capture microdissection as previously described (Kurose K
et al. Hum Mol Genet 2001) to enrich the neoplastic com-
ponent. We subjected those samples to PCR-based semi-
automated double stranded nucleotide sequencing, per
routine of the Eng lab [24,25]. Exons 18–21 (exon-intron
junctions and flanking intronic regions) of EGFR  were
amplified using the primers and conditions described by
Lynch et al [3] and those of ERBB2 were amplified using
the primers and conditions described by Stephens et al
[6]. Double stranded sequencing was performed with the
ABI-3700. Mutations or variants were confirmed in both
directions as well as confirmed by a second independent
PCR reaction. All samples were tested against matched
germline DNA derived from the related normal organ.
Our samples were acquired on anonymised archived
materials without personal identifiers, on an exempt pro-
tocol approved by the Ohio State University Institutional
Review Board.
Results
All hepatoma and biliary cancers samples were negative
for gain-of-function somatic mutations affecting the cata-
lytic domain of the EGFR gene. Power calculations suggest
that our negative results predict that no more than 3% of
hepatoma or biliary cancers would eventually be found to
carry such mutations. As a positive control for mutation
detection, we sequenced EGFR exons 18–21 in 44 adeno-
carcinoma of the lung and found 2 (5%) with somatic
delE746-A750 mutations, previously reported to be asso-
ciated with gefitinib responsiveness. In contrast, 2 (11%)
of the 18 hepatoma had a single novel somatic H878Y
(CAT to TAT; c.2632C > T) mutation in exon 21 of ERBB2
(figure 1), while none of the biliary cancers were found to
have somatic mutations. None of the matched normal tis-
sue was found to have somatic mutations for EGFR or
ERBB2 found in the tumors. These are different from the
reported mutations in non-small cell lung carcinomas.
The H878Y missense mutation occurring in the activation
domain of ERBB2 alters a basic hydrophilic residue to an
acidic hydrophilic residue, and so is predicted to affect
function.
Discussions and Conclusion
The lack of effective treatment for hepatobiliary tumors
indicates a need for more effective therapeutic options.
Emerging targeted therapies including EGFR inhibitors
are offering promise in a variety of malignancies including
hepatobiliary tumors. From this study, we conclude that
gain-of-function somatic mutations affecting the catalytic
domain of EGFR as described in non-small cell lung carci-
nomas have a predicted low yield in hepatoma and biliaryBMC Cancer 2006, 6:278 http://www.biomedcentral.com/1471-2407/6/278
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Somatic missense mutation, H878Y, found in genomic DNA from hepatoma (top chromatogram) but not in corresponding  normal tissue (bottom panel) Figure 1
Somatic missense mutation, H878Y, found in genomic DNA from hepatoma (top chromatogram) but not in corresponding 
normal tissue (bottom panel).BMC Cancer 2006, 6:278 http://www.biomedcentral.com/1471-2407/6/278
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cancers. A recently published study showed the lack of
somatic mutations in EGFR tyrosine kinase domain in
100 hepatocellular carcinomas confirming our findings
[26]. In contrast, we showed that 11% of hepatocellular
carcinomas tested have an ERBB2 mutation occurring in
the activation domain. None were found in biliary cancer
specimens. Given the availability of agents interfering
with ERBB2 signaling and the established role of ERBB2 in
the  EGFR  signaling pathway, we speculate that these
newly described mutations may play a role in predicting
response to EGFR-targeted therapy in hepatoma in pre-
dicting response to agents that target ERBB2 and/or EGFR
in hepatoma. Interestingly, one such agent, lapatinib (a
dual  EGFR/ERBB2  TKI), was recently reported to have
activity in hepatomas (TGCR = 40%) but not in biliary
cancers (TGCR = 26%) [27]. Cohen et al showed that in
head and neck cancers although responses to gefitinib or
erlotinib were not linked to kinase mutations of EGFR,
one single response case was actually linked to a mutation
in exon 20 of ERBB2 establishing the potential predictive
value of such mutations on responses to agents that target
ERBB2 and/or EGFR [28]. In conclusion, our findings sug-
gest that mutations in the tyrosine kinase domain of
ERBB2  in hepatoma may underlie responsiveness to
agents that target ERBB2 and/or EGFR. This should trigger
similar analysis as part of correlative studies in prospective
studies.
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